1-1 of 1
tumor hyperprogression
Close
Sort by
Journal Articles

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

N. Nora Bennani, MD, Levi D Pederson, Pamela Atherton, Ivana Micallef, MD, Joseph P. Colgan, MD, Gita Thanarajasingam, MD, Grzegorz Nowakowski, MD, Thomas E. Witzig, MD, Andrew L. Feldman, MD, Stephen M Ansell, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 467.
https://doi.org/10.1182/blood-2019-126194
Published: 2019